Literature DB >> 6294202

Measurement of human converting enzyme level by direct radioimmunoassay.

F Alhenc-Gelas, J A Weare, R L Johnson, E G Erdös.   

Abstract

CE was purified from human lung, and antisera were raised in rabbits. Antisera inhibited the activity of the purified enzyme from lung and kidney and the plasma CE of normal persons and sarcoid patients. With antisera at a titer of 1:100,000, a sensitive, direct RIA was developed. CE purified from lung or kidney and CE present in normal and in sarcoid plasma gave parallel logit-log displacement lines, suggesting immunological identity. The level of CE in normal human plasma was 400 +/- 131 ng/ml. In untreated sarcoid patients, the enzyme level and activity increased in parallel. There was a negative correlation (r = -0.81) between enzyme level and diffusing capacity of the lung for CO in sarcoid patients. Synthetic inhibitors such as captopril or MK 421 did not interfere with the RIA, permitting enzyme levels to be monitored in patients undergoing acute inhibitor therapy. During administration of MK 421, CE activity was negligible and plasma levels of CE did not change. In contrast, renin activity increased eightfold during the inhibitor therapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6294202

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  13 in total

Review 1.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

2.  Direct radioimmunoassay of angiotensin-converting enzyme in sera from patients with pulmonary diseases.

Authors:  K Hiwada; Y Inoue; Y Takada; A Hashimoto; H Akutsu; F Kitatani; T Kokubu
Journal:  Lung       Date:  1987       Impact factor: 2.584

3.  Angiotensin I converting enzyme in human intestine and kidney. Ultrastructural immunohistochemical localization.

Authors:  P Bruneval; N Hinglais; F Alhenc-Gelas; V Tricottet; P Corvol; J Menard; J P Camilleri; J Bariety
Journal:  Histochemistry       Date:  1986

4.  Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study.

Authors:  F Cambien; F Alhenc-Gelas; B Herbeth; J L Andre; R Rakotovao; M F Gonzales; J Allegrini; C Bloch
Journal:  Am J Hum Genet       Date:  1988-11       Impact factor: 11.025

5.  Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning.

Authors:  F Soubrier; F Alhenc-Gelas; C Hubert; J Allegrini; M John; G Tregear; P Corvol
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

6.  Different frequencies of angiotensin-converting enzyme genotypes in older hypertensive individuals.

Authors:  B J Morris; R Y Zee; A P Schrader
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

7.  Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes.

Authors:  O Costerousse; J Allegrini; M Lopez; F Alhenc-Gelas
Journal:  Biochem J       Date:  1993-02-15       Impact factor: 3.857

8.  Presence of renin, angiotensinogen, angiotensin II in the lamb anterior pituitary gland: immunocytochemical study after cryoultramicrotomy.

Authors:  S Kettani; V Beldent; M C Rousselet; P Ronco; P Verroust; J P Saint-Andre
Journal:  Histochemistry       Date:  1991

9.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.

Authors:  B Rigat; C Hubert; F Alhenc-Gelas; F Cambien; P Corvol; F Soubrier
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

10.  Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.

Authors:  David G Levitt; Rik C Schoemaker
Journal:  BMC Clin Pharmacol       Date:  2006-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.